HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stuhlmeier, K. M. Search for Related Content PubMed PubMed Citation Articles by Stuhlmeier, K. M.

Effects of Leflunomide on Hyaluronan Synthases (HAS): NF-B-Independent Suppression of IL-1-Induced HAS1 Transcription by Leflunomide ¹

Ludwig Boltzmann Institute for Rheumatology and Balneology, Vienna, Austria

Despite evidence that points to unfettered hyaluronic acid (HA) production as a culprit in the progression of rheumatic disorders, little is known about differences in regulation and biological functions of the three hyaluronan synthase (HAS) genes. Testing the effects of drugs with proven anti-inflammatory effects could help to clarify biological functions of these genes. In this study, we demonstrate that leflunomide suppresses HA release in fibroblast-like synoviocytes (FLS) in a dose-dependent manner. We further demonstrate that leflunomide suppresses HA synthase activity, as determined by ¹⁴C-glucuronic acid incorporation assays. Additional experiments revealed that in FLS, leflunomide specifically blocked the induction of HAS1. HAS2 and HAS3, genes that are, in contrast to HAS1, constitutively expressed in FLS, are not significantly affected. Leflunomide can function as a NF-B inhibitor. However, EMSA experiments demonstrate that at the concentrations used, leflunomide neither interferes with IL-1- nor with PMA-induced NF-B translocation. Furthermore, reconstituting the pyrimidine synthase pathway did not lead to the restoration of IL-1-induced HAS1 activation. More importantly, two tyrosine kinase inhibitors mimicked the effect of leflunomide in that both blocked IL-1-induced HAS1 activation without affecting HAS2 or HAS3. These data point at HAS1 activation as the possible cause for unfettered HA production in rheumatoid arthritis and might explain, at least in part, the beneficial effects of leflunomide treatment. These findings also support the concept that IL-1-induced HAS1 activation depends on the activation of tyrosine kinases, and indicate that leflunomide blocks HA release by suppressing tyrosine kinases rather than through inhibition of NF-B translocation.

This article has been cited by other articles:

				K. M. Stuhlmeier, J. Broll, and B. Iliev NF-KappaB Independent Activation of a Series of Proinflammatory Genes by Hydrogen Sulfide Experimental Biology and Medicine, November 1, 2009; 234(11): 1327 - 1338. [Abstract] [Full Text] [PDF]

				K. M. Stuhlmeier Hyaluronan Production in Synoviocytes as a Consequence of Viral Infections: HAS1 ACTIVATION BY EPSTEIN-BARR VIRUS AND SYNTHETIC DOUBLE- AND SINGLE-STRANDED VIRAL RNA ANALOGS J. Biol. Chem., June 13, 2008; 283(24): 16781 - 16789. [Abstract] [Full Text] [PDF]

				K. M. Stuhlmeier Apis Mellifera Venom and Melittin Block neither NF-{kappa}B-p50-DNA Interactions nor the Activation of NF-{kappa}B, Instead They Activate the Transcription of Proinflammatory Genes and the Release of Reactive Oxygen Intermediates J. Immunol., July 1, 2007; 179(1): 655 - 664. [Abstract] [Full Text] [PDF]

				K. M. Stuhlmeier The Anti-rheumatic Gold Salt Aurothiomalate Suppresses Interleukin-1beta-induced Hyaluronan Accumulation by Blocking HAS1 Transcription and by Acting as a COX-2 Transcriptional Repressor J. Biol. Chem., January 26, 2007; 282(4): 2250 - 2258. [Abstract] [Full Text] [PDF]